- Home
- Articles
- latamerica
- tumor targeting
Refine by
Tumor Targeting Articles & Analysis
69 articles found
Application Examples: Using ApoE as a backbone allows LNDs to be specifically targeted to liver cells; LNDs with an ApoA1 backbone can be used for tumor treatment and can even carry chemotherapy drugs and immune adjuvants for a combined attack. Highlights: Their strong natural targeting properties make them particularly suitable for applications ...
This system allows researchers to target specific DNA sequences within a genome, facilitating the addition, removal, or alteration of genetic information. ...
Antibody-drug conjugates (ADCs) combine potent small-molecule drugs with monoclonal antibodies for targeted cancer therapy. A major challenge is loading enough drug onto each antibody without compromising solubility or circulation time. ...
Additionally, PEGylation protects proteins from aggregation and denaturation, improving shelf-life. 4. Enhanced Tumor Targeting (Passive Accumulation) In oncology, PEGylated drugs benefit from the Enhanced Permeability and Retention (EPR) effect, where leaky tumor vasculature allows selective accumulation of macromolecules. ...
The complex nature of cancer treatment highlights the critical requirement for therapies that show both effectiveness and precise targeting of tumor biology. The conventional treatment approaches fail to accurately target cancer cells, which results in numerous adverse effects while diminishing treatment success. FAP-targeted ...
Glycoprotein 1b on platelet surfaces assists tissue regeneration and injury repair by attaching to von Willebrand factor (vWF) and collagen from damaged blood vessels and when activated P-selectin from platelets becomes externalized it binds to PSGL-1 or CD44 on tumor cells thereby forming a defensive wall against tumor cells. These processes can offer effective ...
Traditional cancer treatments do not possess the necessary precision to target only cancer cells which leads to poor treatment results and harmful side effects. ...
The monoclonal antibody is designed to bind specifically to cancer cells, ensuring that the toxic drug is delivered directly to the tumor, thereby minimizing damage to healthy cells. This targeted approach enhances the therapeutic index of the drug, resulting in improved efficacy and reduced side effects compared to conventional chemotherapy. ...
Watertown, MA – March 24, 2025 – Biopharma PEG, a leading supplier of high-quality polyethylene glycol (PEG) derivatives, highlights its innovative product DSPE-PEG-Mannose, an advanced biomedical polymer with significant potential in drug delivery, tumor-targeted therapy, tissue recognition, and adhesion.Structural Advantages of DSPE-PEG-MannoseDSPE-PEG-Mannose ...
Unlike traditional cancer therapies that often target the tumor directly, these services aim to empower the immune system to recognize and attack cancer more effectively. ...
This combined entity is able to cross the blood-brain barrier (BBB) and blood-brain tumour barrier (BBTB) with systemic injection, and to be targeted to glioma lesions. It has been established in vivo and in vitro experiments and reviews that dual-target peptide-modified RBCNPs exhibit better targeted uptake of gliomas than nanoparticle-based ...
These advancements not only enhance our understanding of the disease but also pave the way for more targeted therapeutic solutions. Tumor models for breast cancer, which include both in vivo and in vitro systems, are crucial for studying the complexities of tumor biology and testing potential treatments. ...
Alfa Cytology has introduced its advanced drug development services for brain tumors. Alfa Cytology, celebrated for its cutting-edge biotech solutions and extensive tumor research expertise, has recently introduced brain tumor drug development services, designed to empower researchers in understanding the intricacies and unique challenges ...
Compared with traditional cytotoxins, ADCs have the advantages of strong targeting, less toxic side effects, etc. They can accurately target tumor cells, reduce side effects, and improve the therapeutic effect.ADC drugs are mainly composed of monoclonal antibodies, linkers, and small molecule cytotoxins. ...
This approach can also help detect metastasis early. Omics Analysis for Brain Tumors Similarly, by integrating data from multiple omics layers, researchers can understand the complex biology of tumors better and develop targeted therapies. ...
Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. ...
ByTempus
MMPs can be used as biomarkers and potential therapeutic targets for certain vascular diseases. The induction of MMPs activity contributes to the disassembly of intercellular junctions and the degradation of ECM, thus overcoming the physical limitations of cell motility and participating in tumor invasion. Thus, they are also targets of ...
Ongoing research and inventions in the field of oncology focus on the development of small molecule drug therapies for use in brain tumor resection. Small molecule drugs are being developed to target and effectively treat brain tumors to improve therapeutic outcomes. ...
Once this bioconjugate is administered, it is absorbed by the tumor cells and the drug is slowly released into the cells. This leads to a longer circulation time for the drug, ensuring that it remains in the body at therapeutic levels for an extended period. ...
Since the FDA approved the first oral small molecule targeted therapy for tumors-tamoxifen targeting the estrogen receptor (ER)-in 1977 for the treatment of breast cancer, small molecule drug development has typically focused on screening for high-affinity inhibitors. ...